Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,1-dichloroethene | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | vinylidene chloride results in decreased expression of SLC16A9 mRNA | CTD | PMID:26682919 | 1,2-dimethylhydrazine | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of SLC16A9 mRNA | CTD | PMID:22206623 | 17beta-estradiol | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Estradiol results in increased expression of SLC16A9 mRNA | CTD | PMID:31614463 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of SLC16A9 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SLC16A9 mRNA | CTD | PMID:33956508 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC16A9 mRNA | CTD | PMID:19933214 | 2-methylcholine | affects expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | beta-methylcholine affects the expression of SLC16A9 mRNA | CTD | PMID:21179406 | 3-chloropropane-1,2-diol | increases expression | EXP | | 6480464 | alpha-Chlorohydrin results in increased expression of SLC16A9 mRNA | CTD | PMID:28522335 | 4,4'-sulfonyldiphenol | increases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | bisphenol S results in increased expression of SLC16A9 mRNA | CTD | PMID:30951980 | 4-hydroxyphenyl retinamide | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of SLC16A9 mRNA | CTD | PMID:28973697 | aflatoxin B1 | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased expression of SLC16A9 mRNA | CTD | PMID:22100608 | aflatoxin B1 | decreases methylation | ISO | SLC16A9 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of SLC16A9 gene | CTD | PMID:27153756 | antirheumatic drug | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Antirheumatic Agents results in increased expression of SLC16A9 mRNA | CTD | PMID:24449571 | aristolochic acid A | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of SLC16A9 mRNA | CTD | PMID:33212167 | arsenite(3-) | multiple interactions | ISO | Slc16a9 (Mus musculus) | 6480464 | TRP53 protein affects the reaction [arsenite results in decreased expression of SLC16A9 mRNA] | CTD | PMID:18929588 | arsenite(3-) | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | arsenite results in decreased expression of SLC16A9 mRNA | CTD | PMID:18929588 | avobenzone | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | avobenzone results in decreased expression of SLC16A9 mRNA | CTD | PMID:31016361 | benzo[a]pyrene | increases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of SLC16A9 mRNA | CTD | PMID:27195522 | benzo[a]pyrene | increases methylation | ISO | SLC16A9 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of SLC16A9 promoter | CTD | PMID:27901495 | benzo[a]pyrene | affects methylation | ISO | SLC16A9 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of SLC16A9 5' UTR | CTD | PMID:27901495 | benzo[b]fluoranthene | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | benzo(b)fluoranthene results in decreased expression of SLC16A9 mRNA | CTD | PMID:26377693 | bis(2-chloroethyl) sulfide | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Mustard Gas results in decreased expression of SLC16A9 mRNA | CTD | PMID:25102026 | bisphenol A | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | bisphenol A results in decreased expression of SLC16A9 mRNA | CTD | PMID:26063408 | bisphenol A | increases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | bisphenol A results in increased expression of SLC16A9 mRNA | CTD | PMID:32156529 | bisphenol A | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of SLC16A9 gene | CTD | PMID:31601247 | bisphenol A | increases methylation | ISO | SLC16A9 (Homo sapiens) | 6480464 | bisphenol A results in increased methylation of SLC16A9 gene | CTD | PMID:31601247 | bisphenol A | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | bisphenol A results in increased expression of SLC16A9 mRNA | CTD | PMID:29275510 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of SLC16A9 mRNA | CTD | PMID:25181051 | bisphenol F | increases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | bisphenol F results in increased expression of SLC16A9 mRNA | CTD | PMID:30951980 | cadmium atom | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SLC16A9 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SLC16A9 mRNA | CTD | PMID:35301059 | carbamazepine | affects expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Carbamazepine affects the expression of SLC16A9 mRNA | CTD | PMID:25979313 | carbon nanotube | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | ciguatoxin CTX1B | affects expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Ciguatoxins affects the expression of SLC16A9 mRNA | CTD | PMID:18353800 | cisplatin | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Cisplatin results in decreased expression of SLC16A9 mRNA | CTD | PMID:27392435 | copper atom | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in decreased expression of SLC16A9 mRNA | CTD | PMID:20971185 | copper(0) | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [NSC 689534 binds to Copper] which results in decreased expression of SLC16A9 mRNA | CTD | PMID:20971185 | cytarabine | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Cytarabine results in increased expression of SLC16A9 mRNA | CTD | PMID:21198554 | dibutyl phthalate | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Dibutyl Phthalate results in decreased expression of SLC16A9 mRNA | CTD | PMID:21266533 | dioxygen | multiple interactions | ISO | Slc16a9 (Mus musculus) | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of SLC16A9 mRNA | CTD | PMID:30529165 | dorsomorphin | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ethanol | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Ethanol results in increased expression of SLC16A9 mRNA | CTD | PMID:28986285 | ethyl methanesulfonate | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in decreased expression of SLC16A9 mRNA | CTD | PMID:23649840 | folic acid | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Folic Acid results in decreased expression of SLC16A9 mRNA | CTD | PMID:25629700 | formaldehyde | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of SLC16A9 mRNA | CTD | PMID:23649840 | fulvestrant | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of SLC16A9 gene | CTD | PMID:31601247 | lead(0) | affects methylation | ISO | SLC16A9 (Homo sapiens) | 6480464 | Lead affects the methylation of SLC16A9 gene | CTD | PMID:31636367 | leflunomide | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | leflunomide results in increased expression of SLC16A9 mRNA | CTD | PMID:28988120 | levonorgestrel | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SLC16A9 mRNA | CTD | PMID:19074003 | Licochalcone B | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | licochalcone B results in decreased expression of SLC16A9 mRNA | CTD | PMID:33647349 | lipopolysaccharide | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Lipopolysaccharides results in increased expression of SLC16A9 mRNA | CTD | PMID:35811015 | lipopolysaccharide | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of SLC16A9 mRNA | CTD | PMID:35811015 | methoxychlor | affects methylation | EXP | | 6480464 | Methoxychlor affects the methylation of SLC16A9 gene | CTD | PMID:35440735 | methyl methanesulfonate | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in decreased expression of SLC16A9 mRNA | CTD | PMID:23649840 | N-methyl-4-phenylpyridinium | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of SLC16A9 mRNA | CTD | PMID:24810058 | N-Nitrosopyrrolidine | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | N-Nitrosopyrrolidine results in increased expression of SLC16A9 mRNA | CTD | PMID:32234424 | niclosamide | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Niclosamide results in increased expression of SLC16A9 mRNA | CTD | PMID:36318118 | oleic acid | multiple interactions | ISO | Slc16a9 (Mus musculus) | 6480464 | PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC16A9 mRNA] | CTD | PMID:18489776 | ozone | decreases expression | EXP | | 6480464 | Ozone results in decreased expression of SLC16A9 mRNA | CTD | PMID:28623178 | ozone | multiple interactions | ISO | Slc16a9 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of SLC16A9 mRNA and [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of SLC16A9 mRNA | CTD | PMID:34911549 | perfluorononanoic acid | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | perfluoro-n-nonanoic acid results in increased expression of SLC16A9 mRNA | CTD | PMID:32588087 | phenylmercury acetate | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of SLC16A9 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A9 mRNA | CTD | PMID:27188386 | rotenone | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Rotenone results in increased expression of SLC16A9 mRNA | CTD | PMID:29955902 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of SLC16A9 mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sodium arsenite | decreases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of SLC16A9 mRNA | CTD | PMID:37682722 | sodium fluoride | increases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Sodium Fluoride results in increased expression of SLC16A9 mRNA | CTD | PMID:27862939 | sunitinib | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of SLC16A9 mRNA | CTD | PMID:31533062 | temozolomide | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Temozolomide results in increased expression of SLC16A9 mRNA | CTD | PMID:31758290 | testosterone undecanoate | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SLC16A9 mRNA | CTD | PMID:19074003 | testosterone undecanoate | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | testosterone undecanoate results in decreased expression of SLC16A9 mRNA | CTD | PMID:19074003 | thimerosal | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Thimerosal results in increased expression of SLC16A9 mRNA | CTD | PMID:27188386 | trichostatin A | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of SLC16A9 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | SLC16A9 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A9 mRNA | CTD | PMID:27188386 | triptonide | increases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | triptonide results in increased expression of SLC16A9 mRNA | CTD | PMID:33045310 | tunicamycin | increases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Tunicamycin results in increased expression of SLC16A9 mRNA | CTD | PMID:29453283 | valproic acid | decreases expression | ISO | SLC16A9 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of SLC16A9 mRNA | CTD | PMID:28001369 | vancomycin | increases expression | ISO | Slc16a9 (Mus musculus) | 6480464 | Vancomycin results in increased expression of SLC16A9 mRNA | CTD | PMID:18930951 | |